Compound Overview Class of Compound: Peptide Mechanism of Action: GHK-Cu is said to stimulate the synthesis and breakdown of collagen and glycosaminoglycans, as well as modulating the activity of metalloproteinases and their inhibitors
There is no completed human weight-loss trial of 5-Amino-1MQ, so the effect in people remains unproven despite heavy marketing
Reference ranges differ between labs
However, checking local regulatory prescribing pathways remains completely vital for managing your treatment timeline safely and effectively
Compound Receptors Peak trial weight loss Lean mass as share of loss Semaglutide (Ozempic/Wegovy) GLP-1 ~14.9% (STEP-1, 68 wk) ~39% Tirzepatide (Mounjaro/Zepbound) GLP-1 + GIP ~20.9% (SURMOUNT-1, 72 wk) ~25-40% Retatrutide GLP-1 + GIP + GCGR ~24.2% (Phase 2, 48 wk) Comparable class range Best for understanding the takeaway: the percentage of loss that is lean mass is roughly constant across the class
The blend totals 50mg of lyophilized peptide powder in a 1:7:2 ratio (BPC:GHK:TB)